Summary of Significant Accounting Policies (Details) (USD $)	2 Months Ended	12 Months Ended
	Mar. 07, 2013	Dec. 31, 2013	Dec. 31, 2012	Aug. 31, 2013
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		$ 6,225,923	$ 5,373,023
Allowance for doubtful accounts		2,404,659	991,990	257,000
Additional allowance for accounts receivable		690,000
Revenue from pharmaceutical clients		7,789,985	6,852,536
Bad debt expense		3,165,918	1,351,592
Line of credit, expiration date	Mar. 07, 2015
Line of credit, fee for unused portion	0.25%	0.375%
Line of credit, maximum borrowing capacity		2,000,000
Line of credit facility, current borrowing capacity		1,000,000
Line of credit, borrowing base percentage of pharmaceutical accounts receivable			80.00%
Line of credit, interest above prime rate			1.00%
Line of credit, interest charged			5.00%
Line of credit, amount drawn		1,000,000	1,000,000
Required minimum bank balance	4,000,000		4,000,000
Advertising costs		16,677	13,788
Uninsured foreign cash balance		6,969
Line of Credit Facility,Agreement Date		Jul. 14, 2011
Bank line of credit, over-advance amount required to be repaid			298,000
Cash and cash equivalents that exceeded federally insured limits		7,867,276
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage		87.00%	71.00%
Clinical [Member]
Significant Accounting Policies [Line Items]
Receivable Balance,net allowances for doubtful debts		1,892,384	2,549,665
Payment period from the date of invoice		45 days
ResponseDX [Member]
Significant Accounting Policies [Line Items]
Allowance for doubtful accounts		2,404,659	991,990
Bad debt expense		$ 3,165,918	$ 1,351,592